• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Silence Therapeutics Plc

    5/15/25 9:02:25 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Silence Therapeutics plc

    (Name of Issuer)


    Ordinary Shares, nominal value GBP 0.05 per share

    (Title of Class of Securities)


    G8128Y157

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G8128Y157


    1Names of Reporting Persons

    Redmile Group, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,644,841.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,644,841.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,644,841.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Redmile Group, LLC's beneficial ownership of the Issuer's Ordinary Shares ("Ordinary Shares") is comprised of 2,214,947 American Depositary Shares ("ADSs"), each of which represents three Ordinary Shares, that are owned by certain private investment vehicles managed by Redmile Group, LLC. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on 141,674,074 Ordinary Shares outstanding as of January 31, 2025, as reported by the Issuer in its Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission on February 27, 2025 (the "Form 10-K").


    SCHEDULE 13G

    CUSIP No.
    G8128Y157


    1Names of Reporting Persons

    Jeremy C. Green
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,644,841.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,644,841.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,644,841.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Jeremy C. Green's beneficial ownership of Ordinary Shares is comprised of 2,214,947 ADSs, each of which represents three Ordinary Shares, that are owned by certain private investment vehicles managed by Redmile Group, LLC. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on 141,674,074 Ordinary Shares outstanding as of January 31, 2025, as reported by the Issuer in the Form 10-K.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Silence Therapeutics plc
    (b)Address of issuer's principal executive offices:

    72 Hammersmith Road, London, United Kingdom, W14 8TH
    Item 2. 
    (a)Name of person filing:

    Redmile Group, LLC Jeremy C. Green
    (b)Address or principal business office or, if none, residence:

    Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001
    (c)Citizenship:

    Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom
    (d)Title of class of securities:

    Ordinary Shares, nominal value GBP 0.05 per share
    (e)CUSIP No.:

    G8128Y157
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Redmile Group, LLC - 6,644,841 (1) Jeremy C. Green - 6,644,841 (1)
    (b)Percent of class:

    Redmile Group, LLC - 4.7% (2) Jeremy C. Green - 4.7% (2)
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Redmile Group, LLC - 0 Jeremy C. Green - 0

     (ii) Shared power to vote or to direct the vote:

    Redmile Group, LLC - 6,644,841 (1) Jeremy C. Green - 6,644,841 (1)

     (iii) Sole power to dispose or to direct the disposition of:

    Redmile Group, LLC - 0 Jeremy C. Green - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Redmile Group, LLC - 6,644,841 (1) Jeremy C. Green - 6,644,841 (1) (1) Redmile Group, LLC's and Jeremy C. Green's beneficial ownership of the Issuer's Ordinary Shares is comprised of 2,214,947 ADSs, each of which represents three Ordinary Shares, that are owned by certain private investment vehicles managed by Redmile Group, LLC. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. (2) Percentage based on 141,674,074 Ordinary Shares outstanding as of January 31, 2025, as reported by the Issuer in the Form 10-K.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See the response to Item 4.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Redmile Group, LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member
    Date:05/15/2025
     
    Jeremy C. Green
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Jeremy C. Green
    Date:05/15/2025
    Get the next $SLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLN

    DatePrice TargetRatingAnalyst
    2/11/2025$6.00Sell
    Goldman
    12/2/2024Outperform
    BMO Capital Markets
    9/3/2024$40.00Buy
    Jefferies
    1/31/2024$67.00Outperform
    BMO Capital Markets
    5/8/2023$20.00Overweight
    Morgan Stanley
    12/9/2022$18.00Equal-Weight
    Morgan Stanley
    3/31/2022$33.00Buy
    Chardan Capital Markets
    More analyst ratings

    $SLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Company further extends cash guidance into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights. "Silence delivered another strong quarter focused on clinical and operational execution," said Craig Tooman, President and Chief Executive Officer at Silence. "We remain focused on advancing enrollment into the SANRECO Phase 2 study of divesiran, a first-in-class siRNA program in PV, and continue to be on-track to complete enrollment by the end of this year. We are a

      5/8/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Welcomes Tim McInerney to Board of Directors

      Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

      5/6/25 7:45:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

      Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineer

      3/5/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Leadership Updates

    Live Leadership Updates

    See more
    • Silence Therapeutics Welcomes Tim McInerney to Board of Directors

      Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

      5/6/25 7:45:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

      Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence's Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence's Chairman of the Board, commented, "Alistair has made significant contributions to the Board and the Company over the past nine years. During his time on the Board, the Company has transitioned into a global player focused on the developmen

      4/29/24 8:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

      Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&D at Silence, to ensure an efficient and smooth transition for Dr. Campion's retirement by year-end. Dr. Romano has served as non-execut

      3/28/23 7:05:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Griffiths Richard Ian

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      5/15/25 4:51:57 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Large owner Griffiths Richard Ian

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      5/8/25 7:08:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Large owner Griffiths Richard Ian

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      5/2/25 10:28:34 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Silence Therapeutics with a new price target

      Goldman initiated coverage of Silence Therapeutics with a rating of Sell and set a new price target of $6.00

      2/11/25 7:12:20 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets reiterated coverage on Silence Therapeutics

      BMO Capital Markets reiterated coverage of Silence Therapeutics with a rating of Outperform

      12/2/24 10:09:42 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Silence Therapeutics with a new price target

      Jefferies initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $40.00

      9/3/24 8:14:09 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/14/24 1:13:14 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/14/24 9:44:01 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/12/24 4:31:49 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Silence Therapeutics Plc

      DEF 14A - Silence Therapeutics plc (0001479615) (Filer)

      5/16/25 6:05:34 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Silence Therapeutics Plc

      SCHEDULE 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      5/15/25 9:02:25 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Silence Therapeutics Plc

      10-Q - Silence Therapeutics plc (0001479615) (Filer)

      5/8/25 8:35:12 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Financials

    Live finance-specific insights

    See more
    • Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes," said Craig Tooman, President and CEO of Silence. "In 2025, we are prioritizing investment in programs targeting rare conditi

      2/27/25 7:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

      Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company's website. Deta

      2/13/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

      Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da

      6/27/24 7:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care